Ashion Analytics has introduced new Genomic Enabled Medicine (GEM) Cancer Panel, which will help doctors to treat patients with cancer.
The GEM Cancer Panel is said to cover the coding regions of 562 cancer-related genes and captures copy number events and structural variations.
Featuring state-of-the-art tumor (somatic)-germline subtraction technology, the GEM Cancer Panel provides a detailed genomic analysis of a patient’s cancer.
Ashion Analytics executive vice-president and general manager Michael Demeure said: "Our understanding of genomics today is fundamentally changing the way we view and treat cancer, and we believe the future holds even greater promise.
"As a physician who continues to treat cancer patients, I see every day the critical need to develop better diagnostics as well as new, more effective, and less toxic treatment options."
Ashion Analytics offers precision medicine testing and genomic interpretation services for oncologists and their patients, as well as genomic testing services to support research and pharmaceutical customers.